Compound reference
Retatrutide: structure and analysis
Explore the compounds
Retatrutide is a triple-agonist research candidate supplied for laboratory research. No molecular formula is published for it on this page, because a figure that is not published is not guessed. This page covers its structure, how it is produced, and how identity and purity are established — for a batch, on that batch's certificate of analysis.
What is Retatrutide?
Retatrutide is a synthetic single-molecule agonist at three receptors — GIP, GLP-1 and glucagon. It is a clinical-stage investigational compound and is not an approved medicine in any jurisdiction.
Designing one peptide to engage three related receptors requires a sequence that is a composite rather than a copy of any single native hormone, which makes it a more complex molecule than a fragment or a simple analog.
Reta is an informal abbreviation for Retatrutide. The catalogue uses the compound name, and the certificate issued against each batch specifies the material.
How is Retatrutide produced?
Produced synthetically and supplied lyophilized. This is a clinical-stage investigational compound and is not an approved medicine in any jurisdiction.
The catalogue uses the compound name. Refer to the certificate for the specific batch for its analytical results, methods and specifications.
What is the molecular weight of Retatrutide?
No molecular formula is published for Retatrutide on this page. A figure that is not published is not guessed: an invented mass or sequence is worse than an absent one, because it is a number a reader would have to disprove.
What establishes the material in a specific vial is the identity method and result stated on that batch's certificate, together with the laboratory that issued it.
What is the sequence of Retatrutide?
No one-letter amino-acid sequence is published for Retatrutide on this page. The records this page cites are the parent hormones rather than the analog, and the composite chain carries structural modifications that standard one-letter notation does not express without inventing symbols.
What establishes the material in a specific vial is the identity method and result stated on that batch's certificate, not a notation on a reference page.
How is the identity of Retatrutide confirmed?
Mass spectrometry can compare the measured mass with the expected mass, including structural modifications. Consult the batch certificate for the actual identity method and result; this reference does not establish which assay was run on a supplied vial.
For a composite sequence of this kind, a species missing a modification is a distinct compound with a distinct mass rather than a minor variant, so the identity result is doing substantive work.
Which impurities can appear in Retatrutide?
Longer, more elaborate synthetic sequences carry more coupling steps and therefore a broader set of plausible deletion and truncation products. Chromatographic resolution of closely related species is correspondingly more demanding than for a short peptide.
Because the compound is investigational rather than approved, there is no pharmacopoeial monograph to test against. The specification on its certificate is the reference, which is a reason to read that certificate rather than assume a standard.
What does a certificate of analysis for Retatrutide report?
A certificate for a batch of this material names the batch, names the issuing laboratory, and states for each parameter both the method used and the specification the result was measured against. Identity and purity are the two core results; net peptide content states how much of the fill weight is actually peptide.
A certificate belongs to a batch, not to a product line. When a new batch is released it is tested again, and the certificate published against it is that batch's certificate — a previous batch's result is never carried forward.
Is Retatrutide for human use?
No. This page describes structure and analysis. It makes no claim about what this compound does, and none should be inferred from it. Material is supplied for laboratory research use only: it is not a drug, food, dietary supplement, cosmetic or medical device, it is not for human or veterinary consumption, and no dosing, administration or reconstitution guidance is provided for any such use.
References
- Pro-glucagon — human — UniProt Knowledgebase
- Gastric inhibitory polypeptide — human — UniProt Knowledgebase
- Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide — PubMed, 2024
From the catalog
Compounds referenced on this page
For laboratory research use only. Not for human or veterinary consumption.